• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

快速检索引用检索图表检索高级检索

中国医药导刊 ›› 2022, Vol. 24 ›› Issue (12): 1238-1241.

• 中医中药 • 上一篇    下一篇

风湿祛痛胶囊对糖尿病肾病患者的疗效及对血清内脏脂肪素的影响

王雪玲1, 陈小兵2, 赵舒平3   

  1. 宝鸡市扶风县人民医院肾病糖尿病科1, 影像科2, 神经内科3, 陕西 宝鸡 722200
  • 收稿日期:2022-12-16 修回日期:2021-12-06 出版日期:2022-12-28 发布日期:2022-12-28

Effects of Fengshi Qutong Capsule on Diabetic Nephropathy and Serum Visfatin

  1. Department of Nephropathy and Diabetes1, Department of Radiology2, Department of Neurology3,
         Baoji Fufeng County People′s Hospital, Shaanxi Baoji 722200, China
  • Received:2022-12-16 Revised:2021-12-06 Online:2022-12-28 Published:2022-12-28

摘要: 目的:探讨风湿祛痛胶囊对糖尿病肾病(diabetic nephropathy,DN)患者的疗效及对DN患者血清内脏脂肪素(visfatin,VF)水平的影响。方法:选取2019年6月至2021年6月于我院治疗的DN患者90例,随机分为对照组及研究组,每组各45例。对照组接受常规西医治疗,研究组在对照组治疗的基础上加用风湿祛痛胶囊治疗。比较两组患者治疗前后血糖、血脂、肾功能相关指标及血清VF水平。结果:治疗前,两组患者的血糖、血脂、肾功能及血清VF水平等指标相比,差异均无统计学意义(P>0.05)。治疗后,两组患者空腹血糖(FBG)、餐后2 h血糖(2hBG)、糖化血红蛋白(HbA1c)水平较治疗前均降低(P<0.05),且研究组患者2hBG、HbA1c水平均低于对照组(P<0.05);治疗后,两组患者血肌酐(Scr)、血尿素氮(BUN)、胱抑素C(Cys-C)、尿白蛋白排泄率(UAER)水平均降低(P<0.05),且研究组降低幅度较对照组更明显(P<0.05);两组患者治疗后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平均降低(P<0.05),且研究组降低幅度较对照组更明显(P<0.05);高密度脂蛋白胆固醇(HDL-C)水平升高(P<0.05),且研究组升高幅度较对照组更为明显(P<0.05);治疗后,两组患者血清VF水平均降低(P<0.05),且研究组患者血清VF水平低于对照组(P<0.05)。结论:风湿祛痛胶囊可有效改善DN患者的糖脂代谢及肾功能,其机制可能与降低血清VF水平有关。

关键词: font-size:medium, ">糖尿病肾病;风湿祛痛胶囊;内脏脂肪素

Abstract: Objective:To investigate the efficacy of fengshi qutong capsule on patients with diabetic nephropathy (DN) and its influence on serum visfatin (VF) level in DN patients. Methods: A total of 90 DN patients treated in our hospital from June 2019 to June 2021 were randomly divided into the control group and the study group, with 45 cases in each group. The control group received conventional western medicine treatment, and the study group was treated with fengshi qutong capsule on the basis of the control group. The levels of blood glucose, blood lipids, renal function and serum VF of the two groups of patients were compared before and after the treatment.Results: Before treatment, the levels of blood glucose, blood lipids, renal function and serum VF of the two groups of patients had no statistical difference (P>0.05). After treatment, the levels of fasting blood glucose (FBG), 2 h postprandial blood glucose (2hBG) and glycosylated hemoglobin A1c(HbA1c)of the two groups of patients all decreased compared with those before treatment (P<0.05), and the levels of 2hBG and HbA1c of patients in the study group were lower than those of the control group (P<0.05). After treatment, the levels of serum creatinine (Scr), blood urea nitrogen (BUN), cystatin C (Cys-C) and urinary albumin excretion rate (UAER)of the two groups of patients all decreased (P<0.05), and the reduction of the study group was more obvious than that of the control group (P<0.05). After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) of the two groups of patients all decreased (P<0.05), and the reduction in the study group was more obvious than that of the control group (P<0.05). After treatment,the level of high density lipoprotein cholesterol (HDL-C) of the two groups of patients increased(P<0.05), and the increase of the HDL-C level of patients in the study group was more obvions than that of the control group (P<0.05). After treatment, the serum VF level of the two groups of patients decreased (P<0.05), and the reduction of serum VF level of patients in the study group was more obvious than that of the control group(P<0.05). Conclusion: Fengshi qutong capsule can effectively improve the glucose and lipid metabolism and renal function of DN patients, and the mechanism may be related to the decrease of serum VF level.

Key words: font-size:medium, ">Diabetic nephropathy; Fengshi qutong capsule; Visfatin

中图分类号: